NICE TA438: for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. (Terminated appraisal). (Decision date - May 2017).
RED
NICE TA536 - for untreated ALK-positive advanced non-small-cell lung cancer. (Decision date - September 2018)
Red Drug Classifications
1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
